Table of the basic static CYP induction risk
static_cyp_induction_risk_table.RdTable of the basic static CYP induction risk
Arguments
- perp
The perpetrator object or a list thereof.
- cyp_ind
The CYP induction data as data frame. The following fields are expected:
'name' The name of the perpetrator compound as character.
'cyp' The CYP enzyme as (upper case) character.
'emax' The \(E_{max}\), i.e., the maximum induction effect determined in vitro as numeric.
'ec50' The \(EC_{50}\) in \(\mu M\) as numeric.
'maxc' The maximal concentration in \(\mu M\) tested in the in vitro assay as numeric.
'source' Optional source information as character.
- na.rm
Switch to define whether rows with lacking \(E_{max}\) data are removed from the output. Defaults to
FALSE.- show_dose
Show perpetrator dose in table title, defaults to
FALSE.
Examples
static_cyp_induction_risk_table(examplinib_parent,
examplinib_cyp_induction_data)
#>
#>
#> Table: Risk for hepatic CYP induction by examplinib, basic mRNA fold-change method
#>
#> |CYP | $E_{max}$| $max c$ ($\mu M$)|source | $max c/C_{max,ss,u}$|risk |notes |
#> |:-------|---------:|-----------------:|:---------|--------------------:|:----|:-----------------------------|
#> |CYP1A2 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2B6 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2C8 | NA| NA| | NA| | |
#> |CYP2C9 | NA| NA| | NA| | |
#> |CYP2C19 | NA| NA| | NA| | |
#> |CYP2D6 | NA| NA| | NA| | |
#> |CYP3A4 | 7.35| 3|study 007 | 18.2|Yes | |
static_cyp_induction_risk_table(examplinib_compounds,
examplinib_cyp_induction_data)
#>
#>
#> Table: Risk for hepatic CYP induction by examplinib, basic mRNA fold-change method
#>
#> |CYP | $E_{max}$| $max c$ ($\mu M$)|source | $max c/C_{max,ss,u}$|risk |notes |
#> |:-------|---------:|-----------------:|:---------|--------------------:|:----|:-----------------------------|
#> |CYP1A2 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2B6 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2C8 | NA| NA| | NA| | |
#> |CYP2C9 | NA| NA| | NA| | |
#> |CYP2C19 | NA| NA| | NA| | |
#> |CYP2D6 | NA| NA| | NA| | |
#> |CYP3A4 | 7.35| 3|study 007 | 18.2|Yes | |
#>
#>
#> Table: Risk for hepatic CYP induction by M1, basic mRNA fold-change method
#>
#> |CYP | $E_{max}$| $max c$ ($\mu M$)|source | $max c/C_{max,ss,u}$|risk |notes |
#> |:-------|---------:|-----------------:|:---------|--------------------:|:----|:-----|
#> |CYP1A2 | 1.00| 5|study 007 | 203.3|No | |
#> |CYP2B6 | 6.98| 5|study 007 | 203.3|Yes | |
#> |CYP2C8 | NA| NA| | NA| | |
#> |CYP2C9 | NA| NA| | NA| | |
#> |CYP2C19 | NA| NA| | NA| | |
#> |CYP2D6 | NA| NA| | NA| | |
#> |CYP3A4 | 22.70| 5|study 007 | 203.3|Yes | |
static_cyp_induction_risk_table(examplinib_compounds,
examplinib_cyp_induction_data, show_dose = TRUE)
#>
#>
#> Table: Risk for hepatic CYP induction by examplinib (450 mg), basic mRNA fold-change method
#>
#> |CYP | $E_{max}$| $max c$ ($\mu M$)|source | $max c/C_{max,ss,u}$|risk |notes |
#> |:-------|---------:|-----------------:|:---------|--------------------:|:----|:-----------------------------|
#> |CYP1A2 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2B6 | 1.00| 5|study 007 | 30.3|No |Risk cannot be fully excluded |
#> |CYP2C8 | NA| NA| | NA| | |
#> |CYP2C9 | NA| NA| | NA| | |
#> |CYP2C19 | NA| NA| | NA| | |
#> |CYP2D6 | NA| NA| | NA| | |
#> |CYP3A4 | 7.35| 3|study 007 | 18.2|Yes | |
#>
#>
#> Table: Risk for hepatic CYP induction by M1, basic mRNA fold-change method
#>
#> |CYP | $E_{max}$| $max c$ ($\mu M$)|source | $max c/C_{max,ss,u}$|risk |notes |
#> |:-------|---------:|-----------------:|:---------|--------------------:|:----|:-----|
#> |CYP1A2 | 1.00| 5|study 007 | 203.3|No | |
#> |CYP2B6 | 6.98| 5|study 007 | 203.3|Yes | |
#> |CYP2C8 | NA| NA| | NA| | |
#> |CYP2C9 | NA| NA| | NA| | |
#> |CYP2C19 | NA| NA| | NA| | |
#> |CYP2D6 | NA| NA| | NA| | |
#> |CYP3A4 | 22.70| 5|study 007 | 203.3|Yes | |